FDA approves new rapid cancer diagnostic test

02/18/2013 | GenomeWeb Daily News (free registration)

Dako has received approval from the FDA to market its HER2 IQFISH pharmDx test, which is used to cut the turnaround time for cancer diagnosis from the industry standard of two days to three and a half hours. The test, which identifies the HER2 gene in breast cancer diagnosis, is the first FDA-approved test that works with Dako's IQISH system, the company said.

View Full Article in:

GenomeWeb Daily News (free registration)